Compare iShares Global Tech ETF (IXN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Global Tech ETF trades at $142.04 (market cap $9.75B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Global Tech ETF is the larger of the two by market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IXN | SYRE | |
|---|---|---|
Market Cap | $9.75B | $7.52B |
Volume | 365,991 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $108.92 |
52-Week Low | $95.76 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN (iShares Global Tech ETF) trades at $147.07, down 0.49% on the day but maintains a bullish technical signal with strong moving average support. The ETF recently hit a 52-week high, reflecting momentum despite current consolidation. Technical indicators show mixed signals with neutral RSI readings but bearish ADX trends, while support levels cluster around $146-147.
The outlook remains constructive given the ETF's exposure to global technology leaders and attractive valuation metrics. Key risks include concentration in tech stocks and AI sector volatility. Analyst sentiment appears positive with recent buy ratings citing compelling valuations and long-term growth potential in the global tech landscape.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
